- ISIN
- US4525253062
- CUSIP
- 452525306
- Sector
- Healthcare
- Industry
- Biotechnology
- IPO Date
- Apr 30, 1987
Highlights
- Market Cap
- $101.41M
- Enterprise Value
- $102.02M
- EPS (TTM)
- -$0.06
- Total Revenue (TTM)
- $29.93M
- Gross Profit (TTM)
- $12.75M
- EBITDA (TTM)
- $4.46M
- Year Range
- $4.52 - $12.10
- ROA (TTM)
- -1.24%
- ROE (TTM)
- -1.87%
- Avg. Volume (1M)
- 29K
- Avg. Volume Value (1M)
- $313.46K
Share Price Chart
Loading charts...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
ICCC Performance Chart
ImmuCell Corporation (ICCC) is up 82.3% since the beginning of the year. At $11 per share, ICCC is trading 7.4% below its 52-week high of $12. Investors who bought $1,000 worth of ICCC shares 5 years ago would now be looking at an investment worth $1,113.
Loading charts...
Compare this symbol against anything
Returns By Period
ImmuCell Corporation (ICCC) has returned 82.28% so far this year and 86.83% over the past 12 months. Over the last ten years, ICCC has returned 4.73% per year, falling short of the S&P 500 Index benchmark, which averaged 13.26% annually.
ImmuCell Corporation
- 1D
- 1.36%
- 1M
- 8.94%
- 6M
- 86.21%
- YTD
- 82.28%
- 1Y
- 86.83%
- 3Y*
- 27.96%
- 5Y*
- 2.17%
- 10Y*
- 4.73%
- ALL TIME*
- 5.81%
Benchmark (S&P 500 Index)
- 1D
- 0.70%
- 1M
- 0.09%
- 6M
- 7.94%
- YTD
- 9.41%
- 1Y
- 20.07%
- 3Y*
- 17.84%
- 5Y*
- 11.25%
- 10Y*
- 13.26%
- ALL TIME*
- 8.09%
ICCC Monthly Returns History
Based on dividend-adjusted daily data since Jul 10, 1995, ICCC's average daily return is +0.14%, while the average monthly return is +1.55%. At this rate, an investment would double in approximately 3.8 years.
Historically, 49% of months were positive and 51% were negative. The best month was Mar 1996 with a return of +80.0%, while the worst month was Mar 2020 at -34.1%. The longest winning streak lasted 5 consecutive months, and the longest losing streak was 9 months.
On a daily basis, ICCC closed higher 41% of trading days. The best single day was Feb 8, 2000 with a return of +127.3%, while the worst single day was Feb 9, 2000 at -28.5%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -2.11% | 9.14% | -3.65% | 33.65% | 21.04% | -1.86% | 11.54% | 82.28% | |||||
| 2025 | 4.76% | -2.13% | -9.28% | 13.15% | 18.08% | 8.75% | -8.48% | 0.47% | -2.34% | -0.17% | -22.43% | 27.07% | 19.42% |
| 2024 | 4.32% | -0.56% | 0.38% | -7.36% | -13.44% | 14.12% | -16.29% | -7.88% | -2.94% | -0.55% | 14.13% | 25.00% | 1.18% |
| 2023 | 21.70% | -20.53% | -12.63% | -4.56% | -3.05% | 4.82% | 8.60% | -15.10% | 15.83% | -5.43% | -10.10% | 12.11% | -16.56% |
| 2022 | 1.87% | 0.25% | 18.12% | 0.93% | -16.74% | 7.15% | 1.04% | -16.97% | 2.61% | 7.09% | -13.86% | -11.59% | -23.75% |
| 2021 | 57.14% | 12.51% | -8.37% | 13.59% | -10.78% | -2.76% | 6.00% | -9.04% | 2.18% | -5.98% | 1.48% | -10.41% | 34.46% |
Benchmark Metrics
ImmuCell Corporation has an annualized alpha of 36.47%, beta of 0.37, and R2 of 0.01 versus S&P 500 Index. Calculated based on daily prices since July 10, 1995.
- This stock participated in 53.80% of S&P 500 Index downside but only 49.73% of its upside - more exposed to losses than it benefited from rallies.
- Beta of 0.37 may look defensive, but with R2 of 0.01 this stock is largely uncorrelated with S&P 500 Index - low beta reflects independence, not downside protection. See the Volatility section for a true picture of this stock's risk.
- R2 of 0.01 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- 36.47%
- Beta
- 0.37
- R²
- 0.01
- Upside Capture
- 49.73%
- Downside Capture
- 53.80%
Return for Risk
Risk / Return Rank
ICCC ranks 82 for risk / return — above 82% of stocks peers on PortfoliosLab. Its historical combined result is among the stronger results in the peer group.
Risk / Return Metrics
The table below present risk-adjusted performance metrics for ImmuCell Corporation (ICCC) and compare them to S&P 500 Index.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| ICCC | Benchmark | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | +0.01 | ||
| Sortino ratioReturn per unit of downside risk | +0.06 | ||
| Omega ratioGain probability vs. loss probability | 1.26 | 1.25 | 0.00 |
| Calmar ratioReturn relative to maximum drawdown | 2.32 | 2.00 | +0.32 |
| Martin ratioReturn relative to average drawdown | 7.69 | 8.49 | -0.80 |
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading charts...
Worst Drawdowns
The table below displays the maximum drawdowns of the ImmuCell Corporation. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the ImmuCell Corporation was 85.30%, occurring on Feb 27, 2009. Recovery took 1615 trading sessions.
The current ImmuCell Corporation drawdown is 5.64%.
Drawdown | Fall | Recovery | Underwater | Related event |
|---|---|---|---|---|
-85.30%Feb 2009 | 4y 2mo | 6y 5mo | 10y 7moDec 2004 - Jul 2015 | Financial crisis2007–2009 |
-82.35%Dec 2000 | 9mo 19d | 3y 12mo | 4y 9moMar 2000 - Dec 2004 | Dot-com crash2000–2002 |
-80.67%Mar 1999 | 3y 12d | 10mo 15d | 3y 10moMar 1996 - Feb 2000 | — |
-70.29%Sep 2024 | 3y 7mo | — | 5y 5moFeb 2021 - now | — |
-65.70%Mar 2020 | 4y 8mo | 10mo 14d | 5y 6moJul 2015 - Feb 2021 | COVID crash2020 |
Drawdown Indicators
| ICCC | Benchmark | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -85.30% | -56.78% | -28.52% |
Max Drawdown (1Y)Largest decline over 1 year | -32.94% | -9.10% | -23.84% |
Max Drawdown (3Y)Largest decline over 3 years | -40.00% | -18.90% | -21.10% |
Max Drawdown (5Y)Largest decline over 5 years | -67.04% | -25.43% | -41.61% |
Max Drawdown (10Y)Largest decline over 10 years | -70.29% | -33.92% | -36.37% |
Current DrawdownCurrent decline from peak | -5.64% | -1.58% | -4.06% |
Average DrawdownAverage peak-to-trough decline | -50.55% | -10.70% | -39.85% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 9.92% | 2.14% | +7.78% |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading charts...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of ImmuCell Corporation over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how ImmuCell Corporation is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PS Ratio
This chart shows the Price-to-Sales (P/S) ratio for ICCC relative to other companies in the Biotechnology industry. Currently, ICCC has a P/S ratio of 3.4. This P/S ratio falls within the average range for the industry, suggesting the stock is fairly valued based on its revenue.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for ICCC in comparison with other companies in the Biotechnology industry. Currently, ICCC has a P/B value of 3.5. This P/B ratio is in line with the industry average, suggesting the stock is valued fairly in relation to its book value.
Income Statement
| TTM | |
|---|---|
Revenue | |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |
Build a portfolio with ICCC
Add ImmuCell Corporation to a portfolio and analyze allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Analyzer with ICCC